In addition, the main action of recently developed diabetes drugs such as dipeptidyl peptidase 4 inhibitor and glucagon-like peptide-1 receptor agonist is to induce the secretion of endogenous insulin to lower the plasma glucose level; this study may provide useful insight for determining strategies and policies in the development of drugs with these novel pharmacological mechanisms. This evidence concerns the gene GLP1R and diabetes mellitus.